{"title":"Risks for Hospitalization and Death with Pimavanserin","authors":"M. Okun","doi":"10.1056/NEJM-JW.NA54185","DOIUrl":null,"url":null,"abstract":"Pimavanserin is a serotonin 5-HT 2A receptor blocker antipsychotic drug approved to treat hallucinations and delusions in patients with Parkinson","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NEJM Journal Watch","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1056/NEJM-JW.NA54185","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Pimavanserin is a serotonin 5-HT 2A receptor blocker antipsychotic drug approved to treat hallucinations and delusions in patients with Parkinson
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
